You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • P168 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the united states

Article metrics

Article menu
Download PDFPDF
Treating Idiopathic Pulmonary Fibrosis
P168 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the united states

 

Online download statistics by month:

Online download statistics by month: November 2016 to August 2024

AbstractFullPdf
Nov 20162404
Dec 20161702
Jan 20174203
Feb 20172403
Mar 20173102
Apr 20172705
May 20173300
Jun 20175106
Jul 20173201
Aug 20173401
Sep 20174503
Oct 20174903
Nov 20173103
Dec 20173000
Jan 20186003
Feb 20181700
Mar 20184202
Apr 20182000
May 20187002
Jun 20184801
Jul 20183603
Aug 20184501
Sep 2018800
Oct 20183000
Nov 20182400
Dec 20184001
Jan 2019601
Feb 20191401
Mar 20192801
Apr 2019800
May 20192401
Jun 20192701
Jul 2019600
Aug 20192100
Sep 20191600
Oct 20191100
Nov 20192604
Dec 20192403
Jan 20202004
Feb 2020903
Mar 20201305
Apr 20201003
May 202023011
Jun 2020905
Jul 20201805
Aug 20201205
Sep 20202704
Oct 20201002
Nov 20201403
Dec 2020802
Jan 2021804
Feb 20211006
Mar 2021601
Apr 2021802
May 2021707
Jun 2021003
Jul 2021004
Aug 2021008
Sep 2021002
Oct 202112017
Nov 20211011
Dec 20211000
Jan 2022502
Feb 20221402
Mar 2022601
Apr 20221000
May 202216010
Jun 20221105
Jul 2022601
Aug 20221002
Sep 20229011
Oct 2022402
Nov 2022806
Dec 20221201
Jan 20231303
Feb 2023400
Mar 2023400
Apr 2023001
May 2023404
Jun 2023401
Jul 2023605
Aug 2023502
Sep 20231002
Oct 2023802
Nov 20231304
Dec 20231202
Jan 2024400
Feb 2024401
Mar 202415026
Apr 2024901
May 202414011
Jun 2024900
Jul 20242701
Aug 20241200
Total16440287